속보 • May 14
Revvity Gains FDA Clearance for Single Platform Automated Testosterone Testing Solution Revvity’s subsidiary Immunodiagnostic Systems (IDS) received FDA clearance for its Total Testosterone automated chemiluminescence immunoassay (ChLIA).
The new Total Testosterone test sits alongside the company’s existing FDA-cleared free testosterone and sex hormone-binding globulin (SHBG) assays.
Together, these assays give labs a full testosterone testing menu on a single automated platform, which can replace more complex methods and simplify clinical workflows.
This clearance points to a broader build-out of Revvity’s specialty diagnostics portfolio, aimed at offering labs more complete testing solutions within one system.
Investors may want to watch how quickly labs adopt this single-platform testosterone testing approach and whether it influences recurring consumables demand and instrument placements over time. Declared Dividend • May 11
Dividend of US$0.07 announced Shareholders will receive a dividend of US$0.07. Ex-date: 17th July 2026 Payment date: 7th August 2026 Dividend yield will be 0.3%, which is about the same as the industry average. Payout Ratios Payout ratio: 13%. Cash payout ratio: 6%. Reported Earnings • May 06
First quarter 2026 earnings: EPS and revenues exceed analyst expectations First quarter 2026 results: EPS: US$0.37. Revenue: US$711.1m (up 7.0% from 1Q 2025). Net income: US$40.9m (down 1.9% from 1Q 2025). Profit margin: 5.8% (down from 6.3% in 1Q 2025). Revenue exceeded analyst estimates by 1.0%. Earnings per share (EPS) also surpassed analyst estimates by 1.4%. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US. 공시 • May 06
Revvity, Inc. Updates Earnings Guidance for the Full Year 2026 Revvity, Inc. Updated earnings guidance for the full year 2026. For the period, the company forecasts total revenue of $2.81-$2.84 billion. 공시 • May 02
Revvity, Inc. announces Quarterly dividend, payable on August 07, 2026 Revvity, Inc. announced Quarterly dividend of USD 0.0700 per share payable on August 07, 2026, ex-date on July 17, 2026 and record date on July 17, 2026. 공시 • Apr 17
Revvity, Inc. Showcases Integrated Cancer Research Solutions At AACR Annual Meeting 2026 Revvity, Inc. was showcasing its latest innovations in cancer research at the AACR Annual Meeting 2026, to be held in San Diego, April 17-22. The Company’s comprehensive suite of research use only (RUO) oncology solutions are designed to elevate preclinical and translational research workflows, helping scientists accelerate discoveries that drive the future of cancer science. The full scope of Revvity’s integrated oncology solutions and reagents that will be on display are designed to support the entire cancer research workflow from sample preparation and assay development, to advanced imaging, detection, and data analysis. By combining innovative technologies with AI-driven insights, Revvity helps researchers generate high-quality, reproducible data and uncover deeper biological insights faster. Attendees will experience several of Revvity’s latest innovations, including: Opera Phenix™ OptIQ high-content screening system for advanced 3D and live-cell imaging; Living Image™ Synergy AI software for multimodal in vivo imaging data analysis; EnVision Nexus™ One multimode plate reader for high-sensitivity detection and performance; AssayMate™ automated workstation for simplified, accessible sample preparation; Dharmacon™ ON-TARGETplus™ 2.0 siRNA for potent on-target mRNA knockdown with siRNA designed against the modern genome; Next-generation reagents and assay solutions, such as ATPlite™ and Spark PLUS UV395™, designed to enhance workflow consistency and data quality. Together, these solutions reflect Revvity’s strategy to deliver integrated technologies that connect workflows, reduce variability, and enable more confident decision-making in cancer research, including advanced cellular imaging, AI-enabled in vivo analysis, high-performance detection, automation, and genomics tools. By bringing together instrumentation, reagents, software, and services, Revvity supports researchers at every stage of the scientific journey, helping overcome complex research challenges, increase productivity, and translate discoveries into meaningful impact. For research use only. Not for use in diagnostic procedures. Not affiliated with or endorsed by AACR. 공시 • Apr 11
Revvity, Inc. to Report Q1, 2026 Results on May 05, 2026 Revvity, Inc. announced that they will report Q1, 2026 results Pre-Market on May 05, 2026 Upcoming Dividend • Apr 10
Upcoming dividend of US$0.07 per share Eligible shareholders must have bought the stock before 17 April 2026. Payment date: 08 May 2026. Payout ratio is a comfortable 14% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of American dividend payers (4.2%). Lower than average of industry peers (0.7%). 공시 • Apr 09
Revvity Inc Announces Signals Biodesign Cloud-Native Molecular Cloning Solution Revvity, Inc. announced that its Revvity Signals Software business is launching Signals BioDesign, a cloud-native molecular cloning solution that streamlines biologics research workflows. Built for biotech and pharma R&D teams, the platform simplifies complex cloning processes and enables scalable, collaborative development in a unified digital environment. It addresses the limitations of desktop tools and overly complex platforms by combining essential cloning methodologies with enterprise-grade collaboration. The Signals BioDesign offering provides a complete solution for designing therapeutic constructs across core cloning workflows including Golden Gate, Gibson assembly, and restriction/ligation, plus primer design, Sanger sequencing analysis, and protein translation in one simple to use application. The solution enables high-throughput combinatorial cloning for up to 1,000 constructs while maintaining workflow simplicity, allowing pharma and biotech researchers to design faster, collaborate seamlessly, and eliminate costly data silos. As the only cloud-native molecular cloning tool with integration in the Signals One platform, the Signals BioDesign solution connects design with existing bioregistration and multi-modal experiment capture in a unified biologics research ecosystem. The cloud-native architecture enables real-time team collaboration, centralized bio-sequence libraries, duplicate checking, monomer management, and granular access controls that desktop tools cannot provide, while multi-tenant SaaS deployment eliminates the administrative overhead and compliance risks associated with desktop software licensing. The Signals BioDesign solution’s AI-ready data infrastructure also positions research teams for future machine learning applications in sequence optimization and predictive design. Revvity will introduce the Signals BioDesign offering at the Bio-IT World Conference & Expo, May 19-21, in Boston, Massachusetts. 공시 • Mar 09
Revvity, Inc., Annual General Meeting, Apr 28, 2026 Revvity, Inc., Annual General Meeting, Apr 28, 2026. Declared Dividend • Feb 08
Dividend of US$0.07 announced Shareholders will receive a dividend of US$0.07. Ex-date: 17th April 2026 Payment date: 8th May 2026 Dividend yield will be 0.3%, which is about the same as the industry average. Payout Ratios Payout ratio: 14%. Cash payout ratio: 6%. 공시 • Feb 05
Revvity, Inc. Unveils New High-Impact Discovery Platforms and Showcases Recent Innovations At SLAS2026 Revvity, Inc. announced the launch of multiple new discovery platforms and technologies at SLAS2026, which are designed to accelerate high-throughput drug discovery workflows. Making their debut at the conference in Boston, February 7-11, are theOpera Phenix OptIQ high-content screening system, the EnVision Nexus One multimode plate reader, and the AssayMate workstation, alongside other recently introduced solutions spanning sample preparation, screening, advanced imaging, and lab automation. At booth #612, Revvity will showcase an expanded portfolio of integrated workflow solutions designed to support discovery programs from early screening through data-driven decision making. Solutions debuting at SLAS2026 include: Opera Phenix OptIQ high- content screening system: Designed to reduce bottlenecks in phenotypic screening and advanced cellular analysis, this system enables quantitative imaging across complex biological models, including 3D organoids and organ-on-chip systems. Peak camera quantum efficiency has increased from 60% to 95%, improving image sensitivity and data quality, and the system is equipped with Phenologic.AI image analysis software that now includes new classification capabilities, such as cell cycle analysis, expanding beyond its previous focus on segmentation. Laser-based autofocus has been enhanced to better support multi-layer sample carriers, and a new Harmony software building block enables detection of organoids in brightfield image stacks. EnVision Nexus One multimode plates reader: The newest addition to the EnVision Nexus family, the EnVision Nexus One delivers the trusted sensitivity and reliability of the EnVision Nexus platform in a streamlined single-detector configuration optimized for high-throughput screening environments. Designed to simplify automation and integration while supporting evolving assay needs, the system provides enhanced sensitivity across TRF, Alpha, and luminescence detection. The EnVision Nexus One is powered by intuitive Kaleido software with 21 CFR Part 11 compliance tools and offers flexible configuration options to support a wide range of laboratory workflows. AssayMate workstation: The compact, benchtop AssayMate liquid handler delivers intelligent automation performance for labs of any size. It supports a wide volume range of 3-1000 uL without requiring head changes, using a fixed 8-channel head and gripper configuration. Intelligent features such as pressure-based liquid level detection (PLLD) and built-in workflow error handling--including detection of missing plate lids--enable reliable operation and quick experiment resumption. A reconfigurable recessed deck accommodates optional modules such as heater shakers, heater coolers, and magnetic blocks, while AssayPREP software provides a user-friendly, drag-and-drop interface that requires minimal training. Recent Insider Transactions Derivative • Feb 03
Key Executive notifies of intention to sell stock Tajinder Vohra intends to sell 6k shares in the next 90 days after lodging an Intent To Sell Form on the 2nd of February. If the sale is conducted around the recent share price of US$105, it would amount to US$602k. Since March 2025, Tajinder's direct individual holding has decreased from 22.63k shares to 19.35k. Company insiders have collectively sold US$335k more than they bought, via options and on-market transactions in the last 12 months. 공시 • Feb 03
Revvity, Inc. Provides Revenue Guidance Full Year Ending January 3, 2027 Revvity, Inc. provided revenue guidance full year ending January 3, 2027. For the fiscal year 2026, the Company forecasts total revenue of $2.96-$2.99 billion, organic revenue growth of 2-3%. Reported Earnings • Feb 02
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: EPS: US$2.06 (down from US$2.31 in FY 2024). Revenue: US$2.86b (up 3.7% from FY 2024). Net income: US$239.9m (down 15% from FY 2024). Profit margin: 8.4% (down from 10% in FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 18%. Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 8% per year. 공시 • Jan 27
Revvity, Inc. Declares Quarterly Dividend, Payable on May 8, 2026 The Board of Directors of Revvity, Inc. declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 8, 2026 to all shareholders of record at the close of business on April 17, 2026. Major Estimate Revision • Jan 14
Consensus EPS estimates increase by 18% The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate increased from US$2.06 to US$2.43. Revenue forecast steady at US$2.84b. Net income forecast to grow 45% next year vs 15% growth forecast for Life Sciences industry in the US. Consensus price target of US$115 unchanged from last update. Share price rose 8.3% to US$112 over the past week. Upcoming Dividend • Jan 09
Upcoming dividend of US$0.07 per share Eligible shareholders must have bought the stock before 16 January 2026. Payment date: 06 February 2026. Payout ratio is a comfortable 14% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of American dividend payers (4.4%). Lower than average of industry peers (0.5%). Buy Or Sell Opportunity • Jan 08
Now 21% undervalued Over the last 90 days, the stock has risen 15% to US$102. The fair value is estimated to be US$128, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.7% over the last 3 years. Earnings per share has declined by 23%. For the next 3 years, revenue is forecast to grow by 5.6% per annum. Earnings are also forecast to grow by 26% per annum over the same time period. 공시 • Dec 17
Revvity, Inc. Introduces Signals Xynthetica, an AI-Augmented Design Platform for Molecular and Materials Discovery Revvity, Inc. announced the introduction of its upcoming Signals Xynthetica™? Models-as-a Service (MaaS) AI offering within the Revvity Signals platform. The Signals Xynthetica offering will enable AI-augmented molecular and materials design, and brings together advanced in-silico generation, predictive modeling, and experimental validation within a single, governed environment that allows scientific teams to iteratively design, test, and refine candidate molecules with increasing confidence. Across life sciences and materials research, the application of artificial intelligence and machine learning is rapidly shifting discovery from trial-and-error experimentation toward predictive, data driven design. While powerful algorithms and models continue to emerge, their real-world impact is limited without tight integration with high-quality experimental data and the workflows scientists already use. The Signals Xynthedica offering is intended to address this gap by embedding models directly into the scientific context, connecting AI predictions with real wet-lab outcomes to drive continuous learning and improvement. The Signals Xyntetica platform will support a wide range of in-silico design approaches, including de novo generation, property prediction, and multi-objective optimization. Delivered as an AI MaaS offering, it enables organizations to access, govern, and apply predictive models without building or maintaining a complex AI infrastructure. Models can be used consistently across projects, refreshed as new data emerges, and evaluated transparently alongside experimental results. The Signals Xynthenica offering is expected to become a cornerstone of Revvity's broader vision for AI-augmented discovery, enabling customers to harness predictive power at scale while maintaining strong governance, data stewardship, and scientific rigor. Pre-registration for customers is underway with early access programs available in firstH 2026. Buy Or Sell Opportunity • Dec 01
Now 20% undervalued Over the last 90 days, the stock has risen 17% to US$102. The fair value is estimated to be US$129, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.7% over the last 3 years. Earnings per share has declined by 23%. For the next 3 years, revenue is forecast to grow by 5.1% per annum. Earnings are also forecast to grow by 29% per annum over the same time period. 공시 • Nov 10
Revvity, Inc. (NYSE:RVTY) entered into a definitive agreement to acquire Advanced Chemistry Development, Inc. Revvity, Inc. (NYSE:RVTY) entered into a definitive agreement to acquire Advanced Chemistry Development, Inc. on November 10, 2025.
The transaction is expected to close late in Q4 2025. Declared Dividend • Nov 09
Dividend of US$0.07 announced Shareholders will receive a dividend of US$0.07. Ex-date: 16th January 2026 Payment date: 6th February 2026 Dividend yield will be 0.3%, which is about the same as the industry average. Payout Ratios Payout ratio: 14%. Cash payout ratio: 6%. Reported Earnings • Oct 28
Third quarter 2025 earnings: EPS misses analyst expectations Third quarter 2025 results: EPS: US$0.41 (down from US$0.76 in 3Q 2024). Revenue: US$698.9m (up 2.2% from 3Q 2024). Net income: US$47.2m (down 49% from 3Q 2024). Profit margin: 6.8% (down from 14% in 3Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 20%. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings. 공시 • Oct 27
Revvity, Inc. (NYSE:RVTY) announces an Equity Buyback for $1,000 million worth of its shares. Revvity, Inc. (NYSE:RVTY) announces a share repurchase program. Under the program, the company will repurchase up to $1,000 million worth of its own shares. The program is valid for 2 years. 공시 • Oct 27
Revvity, Inc. Revises Earnings Guidance for the Full Year Ending December 28, 2025 Revvity, Inc. revised earnings guidance for the full year ending December 28, 2025. For the year, the company expects revenue to be between $2.83 billion to $2.88 billion to reflect recent changes in foreign currency exchange rates and is reaffirming its organic growth guidance of 2% to 4%. 공시 • Oct 25
Revvity, Inc. Appoints Anita Gonzales as Vice President and Chief Accounting Officer, Effective October 23, 2025 On October 23, 2025, the Board of Directors of Revvity, Inc. appointed Anita Gonzales, the Company’s Vice President and Controller, to serve as its Vice President and Chief Accounting Officer, effective October 23, 2025. Mrs. Gonzales, 49, has served as the Company’s Vice President and Controller since May 2023, having joined the Company as Senior Director of Integration and Controllership Initiatives in March 2021. Prior to joining the Company, Mrs. Gonzales was at General Electric Company (“GE”) for ten years. During her tenure at GE, Mrs. Gonzales was Director of Audit and Advisory Practices Corporate division from 2016 to 2021, with responsibility for technical accounting and audit standards of the Corporate Audit Staff. Before that, Mrs. Gonzales held executive roles at GE Aviation including Global Controller-Commercial Engines. Earlier in her career, she held roles of increasing responsibility, up to Senior Manager, at PricewaterhouseCoopers. Mrs. Gonzales holds Master of Public Accounting and Bachelor of Business Administration degrees from the University of Texas at Austin and is a Certified Public Accountant. 공시 • Oct 24
Revvity Board Declares Quarterly Dividend, Payable on February 6, 2026 The Board of Directors of Revvity, Inc. declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on February 6, 2026 to all shareholders of record at the close of business on January 16, 2026. Upcoming Dividend • Oct 10
Upcoming dividend of US$0.07 per share Eligible shareholders must have bought the stock before 17 October 2025. Payment date: 07 November 2025. Payout ratio is a comfortable 12% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of American dividend payers (4.5%). Lower than average of industry peers (0.5%). 공시 • Oct 06
Revvity, Inc. to Report Q3, 2025 Results on Oct 27, 2025 Revvity, Inc. announced that they will report Q3, 2025 results Pre-Market on Oct 27, 2025 공시 • Sep 30
Revvity, Inc. Unveils New AI Software Offering to Transform Preclinical Imaging Analysis Revvity, Inc. announced the launch of its Living Image Synergy AI multimodal analysis software for in vivo imaging researchers. The solution provides a unified platform with AI capabilities for seamless data analysis across optical, microCT, ultrasound, and other modalities--reducing data inconsistencies, streamlining workflows, increasing throughput, and enhancing reproducibility, all with the intention of accelerating scientific discovery. The Living Image Synergy AI software centralizes analysis with a goal of eliminating the need for separate tools and enabling seamless correlation of datasets. Revvity developed this unified approach to help researchers uncover biological insights that might otherwise remain hidden when using isolated systems. To further streamline workflows, the software features intuitive co-registration tools and automated processes that reduce manual tasks and analysis time. Advanced AI algorithms automate image segmentation and region-of-interest (ROI) quantification--traditionally labor-intensive and variable steps in imaging analysis. This helps support high-throughput analysis and allows researchers to more efficiently monitor disease progression and assess therapeutic efficacy with greater accuracy and statistical confidence. 공시 • Sep 22
Revvity, Inc.(NYSE:RVTY) dropped from FTSE All-World Index (USD) Revvity, Inc.(NYSE:RVTY) dropped from FTSE All-World Index (USD) Declared Dividend • Aug 10
Dividend of US$0.07 announced Shareholders will receive a dividend of US$0.07. Ex-date: 17th October 2025 Payment date: 7th November 2025 Dividend yield will be 0.3%, which is about the same as the industry average. Payout Ratios Payout ratio: 12%. Cash payout ratio: 7%. 공시 • Aug 07
Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics Revvity, Inc. announced the launch of pHSense™? reagents, a powerful technology designed to advance internalization studies in drug discovery. pHSense reagents are designed for high-throughput, plate-based workflows and intended for researchers studying G protein-coupled receptors (GPCRs) or antibody-drug conjugates (ADCs). They offer a scalable, accurate, and easy-to-implement solution for monitoring antibody, ADC, or receptor internalization. Developed for use with standard plate readers, pHSense reagents combine a pH-sensitive dye and a time-resolved fluorescence (TRF) readout to allow for the delivery of robust kinetics of internalization and high signal-to- background--even at low endogenous receptor expression levels. Fully compatible with Revvity's multimode detection platforms, pHSense reagents have the potential to significantly enhance detection capability while simplifying integration into existing drug discovery workflows. By enabling more efficient screening and characterization of promising therapeutic candidates, pHSense reagents can help researchers accelerate preclinical development timelines, potentially reducing overall development costs and contributing to more efficient advancement of candidates toward clinical evaluation. With a growing focus on receptor trafficking in drug development and increasing demand for accurate, high-throughput tools, pHSense reagents offer support for emerging trends in oncology and precision medicine, particularly in ADC development. The innovative design focused on addressing major limitations of current offerings such as low throughput and suboptimal signal-to-noise ratios. Reported Earnings • Jul 29
Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2025 results: EPS: US$0.47 (down from US$0.59 in 2Q 2024). Revenue: US$720.3m (up 4.1% from 2Q 2024). Net income: US$55.2m (down 24% from 2Q 2024). Profit margin: 7.7% (down from 11% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) missed analyst estimates by 14%. Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings. 공시 • Jul 29
Revvity, Inc. Updates Earnings Guidance for the Full Year Ending December 28, 2025 Revvity, Inc. updated earnings guidance for the full year ending December 28, 2025. The company is raising its revenue guidance to a range of $2.84 billion to $2.88 billion to reflect recent changes in foreign currency exchange rates and assumes 2% to 4% organic growth. 공시 • Jul 25
Revvity, Inc. Declares Quarterly Dividend, Payable on November 7, 2025 The Board of Directors of Revvity, Inc. declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 7, 2025 to all shareholders of record at the close of business on October 17, 2025. Upcoming Dividend • Jul 11
Upcoming dividend of US$0.07 per share Eligible shareholders must have bought the stock before 18 July 2025. Payment date: 08 August 2025. Payout ratio is a comfortable 12% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of American dividend payers (4.5%). Lower than average of industry peers (0.6%). 공시 • Jul 07
Revvity, Inc. to Report Q2, 2025 Results on Jul 28, 2025 Revvity, Inc. announced that they will report Q2, 2025 results Pre-Market on Jul 28, 2025 공시 • Jun 02
Revvity, Inc. Introduces New IVD Reference Standards for Monitoring Oncology Diagnostic Testing Workflows Revvity, Inc. announced the launch of three Mimix reference standards for IVD use, designed for monitoring of next-generation sequencing (NGS) or droplet digital polymerase chain reacting (ddPCR) assays designed to detect somatic mutations in genomic DNA (gDNA) from human samples for IVD use. These cell line-derived reference standards have undergone appropriate design controls to meet U.S. Food and Drug Administration (FDA) regulatory requirements, which helps laboratories integrate them into existing workflows to support monitoring test performance, assay variation, and to help identify increases in random or systemic errors. Offering the Mimix reference standards for IV D indicates the products have been developed and manufactured in accordance with applicable quality system requirements allowing for improved reliability and precision of these reference standards. The three Mimix reference standards cover key cancer testing applications, which include: Mimix OncoSpan FFPE Reference Standard IVD (HD832-IVD); Mimix OncoSpan gDNA Reference Standard IVD (HD 827-IVD); Mimix Myeloid Cancer Panel, gDNA Reference Standard IVD. 공시 • May 20
Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing Revvity, Inc. announced the launch of its new IDS i20™? analytical random access platform from EUROIMMUN, enabling full automation of chemiluminescence immunoassays (ChLIA). The IDS i20 platform is a CE marked and FDA listed device that allows laboratories to consolidate multiple specialty tests on a unique single instrument with greater reagent capacity and higher test throughput compared to existing offerings. The highly versatile IDS i20 instrument allows users to simultaneously run 20 analytes from six diagnostic specialties on a single device. These specialties include endocrinology, allergy, autoimmune and infectious disease testing, testing for Alzheimer's disease and therapeutic drug monitoring. While specialty assays in these diagnostic areas tend to be processed manually or with semi-automated, low-throughput analyzers, the IDS i20 platform offers labs a new means of more flexible, fully automated ChLIA processing. With the ability to process up to 140 tests per hour (assay dependent), the IDS i20 instrument is the latest addition to the well-established IDS i-device series, built on more than 50 years of experience in medical device design and innovation. The IDS i20 platform features new software offering a high degree of adaptability and scalability, along with a superior graphical user interface that meets the latest standards of ergonomics, usability and cybersecurity. Continuous loading of samples and reagents as well as the integrated cooling of ready-to-use reagent cartridges allow for non-stop operation of the system - maximizing efficiency and minimizing hands-on time. Declared Dividend • May 11
Dividend of US$0.07 announced Shareholders will receive a dividend of US$0.07. Ex-date: 18th July 2025 Payment date: 8th August 2025 Dividend yield will be 0.3%, which is about the same as the industry average. Payout Ratios Payout ratio: 12%. Cash payout ratio: 6%. Reported Earnings • Apr 28
First quarter 2025 earnings: EPS exceeds analyst expectations First quarter 2025 results: EPS: US$0.35 (up from US$0.23 in 1Q 2024). Revenue: US$664.8m (up 2.3% from 1Q 2024). Net income: US$41.7m (up 45% from 1Q 2024). Profit margin: 6.3% (up from 4.4% in 1Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 4.8%. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. 공시 • Apr 28
Revvity, Inc. Updates Earnings Guidance for the Full Year Ending December 28, 2025 Revvity, Inc. updated earnings guidance for the full year ending December 28, 2025. The company is raising its revenue guidance to a range of $2.83-$2.87 billion to reflect recent changes in foreign currency exchange rates and is reaffirming its organic growth guidance of 3-5% for the full year 2025. 공시 • Apr 25
Revvity, Inc. Declares Regular Quarterly Dividend, Payable on August 8, 2025 The Board of Directors of Revvity declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 8, 2025 to all shareholders of record at the close of business on July 18, 2025. 공시 • Apr 23
Revvity, Inc. Fuels the Future of Cancer Science with New Research Solutions Revvity, Inc. is set to unveil the VivoJect™? Image-Guided Injection System as part of its distinguished cancer research and discovery portfolio at the AACR Annual Meeting 2025 in Chicago, April 25-30. Paired with the Vega™? automated preclinical ultrasound system, the VivoJect system allows for real-time imaging and precise, nimble operation for researchers at a higher throughput compared to traditional techniques. It streamlines in vivo imaging workflows for applications such as tumor model creation, targeted drug delivery, gene therapy, stem cell research, and cardiac studies. Revvity will also showcase a broad portfolio of solutions driving advancements in cancer research at its booth (#1200), including the PhenoVue™? DNA Damage Response Staining Kit, Harmony™? 5.3 and Phenologic.AI™? high-content image analysis software and over 120 cell line-derived oncology reference standards from itsimix™? portfolio. BioLegend's reagent innovations will also be on display, including the TotalSeq™? PhenoCyte, TotalSeq-A and -C Universal Cocktails, v2.0, LEGEND MAX™? High Sensitivity Mouse TNF-a and ELISA MAX™? Deluxe Set Human ICAM-1 kits. Key Exhibits at AACR Annual Meeting 2025 Revvity's booth will also feature: Cell analysis in 3D, and AI: Solutions include cell counters and image cytometers, cellular imaging reagents, microplates and analysis software, as well as high-content imaging instruments. Immunoassays: An extensive range of immunoassay technologies including multimode microplate readers and microplates, as well as assay kits and reagents. In vivo imaging: Instruments, reagents, software and related accessories to help accelerate drug development by tracking disease progression, evaluate efficacy, and assess toxicity. Genomic solutions: A wide range of solutions including the Pin-point™? base editing platform, OMNI™? sample homogenizers, liquid handling workstations and more. More than 10 scientific posters authored or co-authored by Revvity employees will be on display. Among them is a poster produced in collaboration with a research team from Charles River Laboratories, which utilized Revvity's Vega automated preclinical ultrasound system in a longitudinal study of the progression of graft versus host disease. For further information on Revvity's cancer research innovations and poster presentations at the AACR Annual meeting 2025, visit booth #1200 or this link. All Revvity offerings mentioned herein are for research use only, and not for use in diagnostic procedures. Upcoming Dividend • Apr 10
Upcoming dividend of US$0.07 per share Eligible shareholders must have bought the stock before 17 April 2025. Payment date: 09 May 2025. Payout ratio is a comfortable 12% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of American dividend payers (4.9%). Lower than average of industry peers (0.7%). Buy Or Sell Opportunity • Apr 08
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 21% to US$91.79. The fair value is estimated to be US$118, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 13% over the last 3 years. Earnings per share has declined by 54%. For the next 3 years, revenue is forecast to grow by 5.2% per annum. Earnings are also forecast to grow by 20% per annum over the same time period. 공시 • Apr 03
Revvity, Inc. to Report Q1, 2025 Results on Apr 28, 2025 Revvity, Inc. announced that they will report Q1, 2025 results Pre-Market on Apr 28, 2025 공시 • Apr 02
Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test Revvity, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT™.TB test. Initially launched outside the U.S. in 2024, this powerful combination allows laboratories to improve productivity while maintaining superior clinical performance in latent tuberculosis (TB) detection. This milestone marks a significant advancement in the fight against TB with a faster high-throughput solution delivering accurate diagnostic results to support timely treatment and containment in the U.S. as well as other locations around the world. Key Features of the Automated Latent Tuberculosis Test: The Auto-Pure 2400 system seamlessly integrates liquid handling and magnetic cell isolation technology. The Auto-Pure 2400 system streamlines lab workflows, testing up to 24 samples per run, completing Day 1 of the T-SPOT.TB testing in under 3.5 hours with only a single mid-run user interaction. The WHO identifies T-SPOT.TB as the only ELISPOT-based IGRA. This methodology, with its added cell number normalization step, ensures reproducible results by minimizing the impact of pre-analytical variables seen in other IGRAs. The T-SPOT.TB test delivers key advantages, including fewer indeterminate results, reduced need for repeat testing, and consistent performance in immunocompromised patients. 공시 • Feb 27
Revvity, Inc., Annual General Meeting, Apr 22, 2025 Revvity, Inc., Annual General Meeting, Apr 22, 2025. Declared Dividend • Feb 09
Dividend of US$0.07 announced Shareholders will receive a dividend of US$0.07. Ex-date: 17th April 2025 Payment date: 9th May 2025 Dividend yield will be 0.2%, which is lower than the industry average of 0.4%. Payout Ratios Payout ratio: 12%. Cash payout ratio: 6%. Reported Earnings • Feb 01
Third quarter 2024 earnings released: EPS: US$0.76 (vs US$0.26 in 3Q 2023) Third quarter 2024 results: EPS: US$0.76 (up from US$0.26 in 3Q 2023). Revenue: US$684.0m (up 2.0% from 3Q 2023). Net income: US$93.4m (up 188% from 3Q 2023). Profit margin: 14% (up from 4.8% in 3Q 2023). Revenue is forecast to grow 5.1% p.a. on average during the next 4 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance. Recent Insider Transactions Derivative • Jan 31
Senior VP of Administration notifies of intention to sell stock Joel Goldberg intends to sell 15k shares in the next 90 days after lodging an Intent To Sell Form on the 30th of January. If the sale is conducted around the recent share price of US$127, it would amount to US$1.9m. Since March 2024, Joel's direct individual holding has decreased from 104.61k shares to 97.11k. Company insiders have collectively sold US$818k more than they bought, via options and on-market transactions in the last 12 months. 공시 • Jan 31
Revvity, Inc. Provides Earnings Guidance for the Fiscal Year 2025 Revvity, Inc. provided earnings guidance for the fiscal year 2025. For the year, the company expects total revenue of $2.80 billion to $2.85 billion. 공시 • Jan 16
Revvity, Inc. Updates Revenue Guidance for the Fourth Quarter of 2024 Revvity, Inc. updated revenue guidance for the fourth quarter of 2024. For the year, the company's Reported and organic revenue growth for the fourth quarter is expected to be approximately 5% and 6%, respectively, as compared to the same period a year ago. This is expected to result in fourth quarter revenue of approximately $730 million. 공시 • Jan 13
Revvity, Inc. to Report Fiscal Year 2024 Results on Jan 31, 2025 Revvity, Inc. announced that they will report fiscal year 2024 results Pre-Market on Jan 31, 2025 Recent Insider Transactions Derivative • Jan 12
Key Executive notifies of intention to sell stock Tajinder Vohra intends to sell 5k shares in the next 90 days after lodging an Intent To Sell Form on the 7th of January. If the sale is conducted around the recent share price of US$117, it would amount to US$642k. Since March 2024, Tajinder's direct individual holding has decreased from 26.11k shares to 19.65k. Company insiders have collectively sold US$818k more than they bought, via options and on-market transactions in the last 12 months. 공시 • Jan 10
Revvity, Inc. Announces Fda Clearance for First Automated Free Testosterone Test Revvity, Inc. announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EUROIMMUN’s automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone. This innovative test is the first of its kind to receive FDA clearance for direct quantitative measurement of free testosterone levels, marking a significant advancement in diagnostic capabilities for androgen disorders. Key features of the new test include: The only FDA-cleared ChLIA assay for direct quantitative measurement of free testosterone in human serum or plasma. Rapid results on EUROIMMUN’s ChLIA platforms with the first result available in just 48 minutes and an estimated throughput of nearly 60 tests per hour. Incorporation of monoclonal antibodies to ensure specificity and consistent performance across test batches. The assay is processed on the Company’s random-access iSYS or i10 instruments to deliver quick turnaround times and high-throughput testing with minimal technician training and expertise, while maintaining superior accuracy and reliability. The assay provides direct measurement of free testosterone levels in a single test, enhancing diagnostic capabilities for conditions such as hypogonadism, impotence, polycystic ovarian syndrome (PCOS), and other androgenital syndromes. Upcoming Dividend • Jan 10
Upcoming dividend of US$0.07 per share Eligible shareholders must have bought the stock before 17 January 2025. Payment date: 07 February 2025. Payout ratio is a comfortable 13% and this is well supported by cash flows. Trailing yield: 0.2%. Lower than top quartile of American dividend payers (4.6%). Lower than average of industry peers (0.5%). Recent Insider Transactions Derivative • Dec 03
CEO, President & Director notifies of intention to sell stock Prahlad Singh intends to sell 18k shares in the next 90 days after lodging an Intent To Sell Form on the 2nd of December. If the sale is conducted around the recent share price of US$116, it would amount to US$2.1m. For the year to December 2017, Prahlad's total compensation was 12% salary and 88% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2024, Prahlad has owned 127.36k shares directly. Company insiders have collectively bought US$18k more than they sold, via options and on-market transactions, in the last 12 months. 공시 • Nov 20
Scale Biosciences and Revvity's BioLegend Launch First-Of-Its-Kind Solution for High Parameter Protein Profiling of Single Cells Scale Biosciences (Scale BioTM) and Revvity's BioLegend business announced the availability of a new, first-of-its-kind TotalSeqTM PhenocyteTM single-cell protein profiling solution that supports customers by more easily identifying and characterizing rare cell subtypes, which ultimately powers immunology and oncology research. The solution is enabled by the proprietary combination of Scale Biosciences' Quantum Barcoding technology platform and BioLegend's TotalSeqTM antibody conjugates. While technologies like mass cytometry and high-parameter flow cytometry enable protein analysis at the single cell level, these approaches require complex panel optimization and sophisticated instrumentation that limit their accessibility and scalability across multiple samples. The new offering builds upon BioLegend's well validated TotalSeq-ATM antibody panels and Scale Bio's Quantum Barcoding technology workflow. The combined offering can be used to power biomarker discovery and the identification of rare cells within a heterogeneous population without complex panel design, complicated workflows, or dedicated instrumentation. The TotalSeq Phenocyte solution is now shipping. Declared Dividend • Nov 10
Dividend of US$0.07 announced Shareholders will receive a dividend of US$0.07. Ex-date: 17th January 2025 Payment date: 7th February 2025 Dividend yield will be 0.2%, which is lower than the industry average of 0.4%. Payout Ratios Payout ratio: 13%. Cash payout ratio: 6%. 공시 • Nov 06
Revvity, Inc. (NYSE:RVTY) announces an Equity Buyback for $1,000 million worth of its shares. Revvity, Inc. (NYSE:PKI) announces a share repurchase program. Under the program, the company will repurchase up to $1,000 million worth of its own shares. The program will expire on November 3, 2026. 
